IBEX 35
11.026,80 +136,60 (+1,25%) Euro Stoxx 50
4.974,81 +37,96 (+0,77%) Dólar/Euro
1,0664 +0,0008 (+0,07%) Petróleo Brent
87,12 +0,12 (+0,14%) Oro
2.309,00 -37,40 (-1,59%) Bitcoin EUR
62.069,98 +234,18 (+0,38%)
Evoke Pharma, Inc. (EVOK)
Después del cierre:
Evoke Pharma, Inc.
420 Stevens Avenue
Suite 230
Solana Beach, CA 92075
United States
858 345 1494
https://www.evokepharma.com
Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 4
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Matthew J. D'Onofrio MBA | Co-Founder, CEO & Director | 779,37k | N/A | 1970 |
| Dr. Marilyn R. Carlson D.M.D., M.D., RAC. | Chief Medical Officer | 681,24k | N/A | 1948 |
| Mr. Christopher Quesenberry | Chief Commercial Officer - Gimoti (TM) | N/A | N/A | N/A |
Descripción
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Gobierno corporativo
El ISS Governance QualityScore de Evoke Pharma, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
